RAS-ing the bar in the treatment of KRAS-mutant cholangiocarcinoma.

Despite progress in elucidating the molecular landscape and actionable vulnerabilities of cholangiocarcinoma, clinical outcomes for patients with advanced disease remain dismal. In this issue of Cancer Cell, Entrialgo-Cadierno et al. raise the bar for the ∼20%-25% of patients with oncogenic KRAS mutations by unlocking the therapeutic potential of direct RAS-GTP inhibition.